Developing Integrin Activators
as First-In-Class Kidney Disease Therapeutics Learn More about our missionOur Lead
ONT01 – A clinical stage, oral, selective, small molecule integrin CD11b agonist for the treatment of lupus nephritis.
Our CellStaple Platform
Our Proprietary AI-enabled CellStaple Platform Identifies Novel Antibody and Small Molecule Therapeutics
Career Opportunities
AlloSite is growing. Apply below
© 2025 Allosite Therapeutics. All rights reserved.